Academy-Led Group to CMS: End Step Therapy in Medicare Advantage
We continue to sound the alarm about the harm caused by elimination of the ban on step therapy for Part B drugs in Medicare Advantage plans.
Member exclusive - Locked
November 8, 2021
Zirabev, Mvasi May Not Be Used to Treat Eye Disease, CMS Says
CMS has told Medicare Advantage plans that the two biosimilars, which are not clinically proven to treat eye disease and are potentially dangerous to ophthalmology patients, may not be used as substitutes for Avastin or be required in their step therapy programs.
Image
Member exclusive - Locked
December 22, 2020
Congress Announces Year-End Deal That Mitigates 2021 Medicare Payment Cuts
Congress’ deal infuses $3 billion into the physician payment system to reduce the negative effect of the policy changes for evaluation and management (E/M) services that the Centers for Medicare & Medicaid Services (CMS) will implement in January.
Member exclusive - Locked
June 17, 2020
Academy Calls for Lifting Originating Site Restrictions, Increased Reimbursement for Telehealth
A recent Academy survey indicated that 13% of our members now say they use telehealth services to treat patients.
